Indian drug makers end generic bids
SOMMAI / Shutterstock.com
India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
301 Priority Watch List; USTR; PhRMA; compulsory licences; Narendra Modi